Conference Proceedings
Paired tumor and cfDNA in patients with HER2-mutant solid tumors treated with neratinib reveals convergence of multiple on-target resistance mechanisms: Results from the SUMMIT "Basket" Trial
Helen H Won, S Duygu Selcuklu, Sarina A Piha-Paul, Cristina Saura, Jordi Rodon, Ingrid A Mayer, Sherene Loi, Geoffrey I Shapiro, Janice Lu, Adam Brufsky, Catherine Zimel, Myra Melcer, Maurizio Scaltriti, Lisa D Eli, Richard E Cutler, Alshad S Lalani, Richard P Bryce, Carlos Arteaga, Funda Meric-Bernstam, Michael F Berger Show all
CANCER RESEARCH | AMER ASSOC CANCER RESEARCH | Published : 2019
Abstract
Abstract Background: Somatic mutations in ERBB2 occur across various tumor types at relatively low frequencies and can lead to constitutive kinase signaling and oncogenic transformation. SUMMIT is an ongoing basket trial of neratinib, an irreversible pan-HER tyrosine kinase inhibitor, in pts with ERBB2 mutant cancers (NCT01953926). Methods: Pts with advanced solid tumors and locally documented ERBB2 mutations received neratinib 240 mg daily (N=8) +/- fulvestrant at the labeled dose for pts with ER+ breast cancer (N=6) as part of the global Phase II SUMMIT basket study. Pre- and post-treatment tumor and cfDNA were subjected to NGS using MSK-IMPACT for tissu..
View full abstract